Stephan Grupp Md Phd

This early-stage trial is testing a new treatment called GPC2 CAR T cells for children with neuroblastoma or retinoblastoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize a…

This early-phase trial is testing a new treatment called CART123 for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. CART123 cells are specially engineered immune cells designed to find and kill leukemia cells. …

This early-stage trial is testing a new type of cell therapy for children with neuroblastoma that has returned or is hard to treat. The therapy uses the patient's own immune cells, which are modified in the lab to recognize and attack a protein called PHOX2B found on neuroblastom…

This study is testing a new version of CAR T-cell therapy for children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to target cancer cells. The trial aims to …

This early-phase study tests a treatment called BEAM-201, made from donor immune cells engineered to attack cancer cells in people with T-cell acute lymphoblastic leukemia or lymphoma that has returned or not responded to standard therapy. Up to 33 children and young adults (ages…

This study is testing a new approach for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. It uses two different types of engineered immune cells (CAR T cells) that target two proteins, CD19 and CD22, on t…

This study tests a personalized cell therapy (CART19) in children and young adults with rare, high-risk forms of B-cell acute lymphoblastic leukemia (B-ALL). The treatment uses the patient's own immune cells, modified to find and kill cancer cells. The goal is to see if this ther…

This study tests whether a stem cell transplant using the patient's own cells can help young people (ages 8 to 25) with life-threatening lupus or scleroderma. The goal is to wipe out the faulty immune system and allow a new, healthy one to grow. The trial will track how long pati…